Expand VRTX Menu
VRTX MENU

VRTX Latest Press Releases

-- July 29, 2026 --

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions Business Wire 7:00 AM

-- July 8, 2026 --

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX Business Wire 12:33 PM
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy PRNewswire 9:01 AM

-- July 7, 2026 --

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd Business Wire 4:00 PM

-- July 6, 2026 --

Vertex to Acquire Crinetics Pharmaceuticals Business Wire 4:04 PM
Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis PRNewswire 10:23 AM

-- July 1, 2026 --

Vertex Announces US FDA Approval for Expanded Use of CASGEVY for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia Business Wire 7:58 PM

-- June 11, 2026 --

Vertex Presents New Data on CASGEVY, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions Business Wire 2:01 AM

-- June 5, 2026 --

Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference Business Wire 12:00 PM

-- June 3, 2026 --

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 Business Wire 4:00 PM

-- June 1, 2026 --

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy Business Wire 8:00 AM

-- May 11, 2026 --

Vertex to Participate in Upcoming May Investor Conferences Business Wire 4:00 PM

-- May 6, 2026 --

Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany Business Wire 7:01 AM

-- May 4, 2026 --

Vertex Reports First Quarter 2026 Financial Results Business Wire 4:01 PM

-- April 6, 2026 --

Vertex to Announce First Quarter 2026 Financial Results on May 4th Business Wire 4:00 PM

-- April 1, 2026 --

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK and TRIKAFTA, Expanding Availability of These Medicines to ~95% of All People With CF in the United States Business Wire 7:30 AM

-- March 9, 2026 --

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy Business Wire 4:02 PM

-- March 5, 2026 --

Vertex to Participate in Upcoming March Investor Conferences Business Wire 4:00 PM
Vertex to Present New Data on JOURNAVX That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures Business Wire 10:00 AM
Market Data Delayed 15 Minutes